tiprankstipranks
Trending News
More News >
Xbrane Biopharma AB (SE:XBRANE)
:XBRANE

Xbrane Biopharma AB (XBRANE) AI Stock Analysis

Compare
4 Followers

Top Page

SE

Xbrane Biopharma AB

(Berlin:XBRANE)

Rating:54Neutral
Price Target:
kr0.50
▲(92.31%Upside)
The overall stock score of 54 reflects significant financial performance challenges due to consistent losses and cash flow issues. These are partially offset by positive technical indicators suggesting a short-term bullish trend. However, the negative valuation due to ongoing losses and absence of dividend yield remains a concern for investors seeking value.

Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)

Xbrane Biopharma AB Business Overview & Revenue Model

Company DescriptionXbrane Biopharma AB is a biotechnology company specializing in the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. The company operates primarily in the pharmaceutical sector, focusing on creating cost-effective and accessible alternatives to existing biologic therapies. Xbrane's core products include biosimilars targeting therapeutic areas such as oncology and ophthalmology.
How the Company Makes MoneyXbrane Biopharma AB generates revenue primarily through the development and commercialization of biosimilar products. The company's revenue model involves partnering with larger pharmaceutical firms to advance biosimilar candidates through clinical trials and regulatory approval processes. These partnerships often include licensing agreements, where Xbrane receives upfront payments, milestone payments, and royalties based on the sale of approved biosimilar products. Additionally, Xbrane may earn revenue from contract development services and collaborations with other biopharmaceutical companies, leveraging its expertise in biosimilar development to support third-party projects. Strategic alliances and out-licensing deals are significant contributors to Xbrane's earnings, enabling the company to share the financial risks and benefits associated with bringing biosimilars to market.

Xbrane Biopharma AB Financial Statement Overview

Summary
Xbrane Biopharma AB faces significant financial challenges, characterized by consistent losses and cash flow issues. Despite a strong gross profit margin and moderate debt-to-equity ratio, the company struggles with profitability and cash generation. The focus should be on improving revenue growth and operational efficiency to ensure long-term sustainability.
Income Statement
40
Negative
Xbrane Biopharma AB has demonstrated a volatile revenue growth trajectory, with a recent decline from the previous year. The company exhibits a negative net profit margin and EBIT margin, indicating ongoing struggles with profitability. Despite a strong gross profit margin, the continuous negative net income presents a significant challenge.
Balance Sheet
45
Neutral
The company's balance sheet reveals a moderate debt-to-equity ratio, which is a positive indicator of leverage management. However, the declining equity ratio suggests increasing liabilities relative to assets. Return on equity remains negative, reflecting poor profitability levels impacting shareholder value.
Cash Flow
35
Negative
Xbrane Biopharma AB's cash flow statement shows negative free cash flow, with a free cash flow to net income ratio indicating substantial cash outflows exceeding net income. The operating cash flow remains negative, suggesting ongoing liquidity challenges. Financing activities have been a key source of cash, highlighting dependency on external funding.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
198.70M238.73M57.62M11.53M6.82M
Gross Profit
180.47M35.39M41.04M-684.00K2.45M
EBIT
-217.92M-310.43M-166.22M-180.40M-224.25M
EBITDA
-181.97M-282.03M-149.34M-167.59M-213.07M
Net Income Common Stockholders
-266.22M-388.17M-172.23M-191.01M-226.79M
Balance SheetCash, Cash Equivalents and Short-Term Investments
124.33M65.40M193.99M295.18M243.14M
Total Assets
842.43M653.51M690.51M688.43M463.76M
Total Debt
191.72M231.48M38.22M44.38M6.26M
Net Debt
67.39M166.08M-155.77M-250.80M-236.88M
Total Liabilities
633.89M482.17M265.63M256.69M206.06M
Stockholders Equity
208.54M171.34M424.89M431.74M257.71M
Cash FlowFree Cash Flow
-185.97M-423.45M-254.04M-296.96M-242.26M
Operating Cash Flow
-133.73M-406.68M-193.92M-219.61M-238.41M
Investing Cash Flow
-52.25M-16.77M-60.13M-77.35M-3.85M
Financing Cash Flow
243.62M298.70M148.86M349.37M322.72M

Xbrane Biopharma AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.26
Price Trends
50DMA
0.22
Positive
100DMA
0.19
Positive
200DMA
0.19
Positive
Market Momentum
MACD
<0.01
Negative
RSI
54.28
Neutral
STOCH
76.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 0.26 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.22, and above the 200-day MA of 0.19, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.28 is Neutral, neither overbought nor oversold. The STOCH value of 76.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.

Xbrane Biopharma AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
kr402.97M-47.73%45.52%93.35%
54
Neutral
$5.38B3.31-45.11%3.29%16.82%0.04%
44
Neutral
kr270.84M-18.79%21.85%
42
Neutral
kr353.76M-24.61%47.06%33.86%
40
Underperform
kr322.81M
1.72%32.54%
36
Underperform
kr182.35M-54.29%-100.00%-17.35%
32
Underperform
kr379.15M-205.65%24.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:XBRANE
Xbrane Biopharma AB
0.25
-0.04
-13.19%
SE:ONCO
Oncopeptides AB
1.52
-1.64
-51.90%
SE:GUARD
Guard Therapeutics International AB
18.00
-18.06
-50.08%
SE:IMMU
Immunicum AB
6.49
-2.89
-30.81%
SE:ISOFOL
Isofol Medical AB
1.15
0.46
66.86%
SE:IVACC
Intervacc AB
1.01
-1.75
-63.50%

Xbrane Biopharma AB Corporate Events

Xbrane Biopharma Announces SEK 240 Million Directed Share Issue to Boost Biosimilar Development
Jun 10, 2025

Xbrane Biopharma AB has announced a directed share issue, subject to approval by an Extraordinary General Meeting, to raise approximately SEK 240 million. This funding will support the company’s regulatory processes, production costs, and general corporate purposes, positioning Xbrane to capitalize on its biosimilar products, Ximluci® and Xdivane™, and potentially achieve cash-flow positivity. The recent transaction with Alvotech, involving the sale of a biosimilar candidate and organizational restructuring, is expected to significantly reduce Xbrane’s fixed costs and enhance its financial flexibility, enabling a stronger focus on its core biosimilar programs.

Xbrane Biopharma Announces Extra General Meeting for Share Issue
Jun 10, 2025

Xbrane Biopharma AB has announced an extra general meeting to discuss a proposed directed issue of shares, which involves issuing up to 1,043,478,260 new shares. This move is aimed at raising capital, with a total potential increase in share capital of SEK 233,933,281.222894. The subscription price is set at SEK 0.23 per share, determined through an accelerated bookbuilding procedure. This strategic decision is expected to strengthen the company’s financial position and support its market expansion efforts, potentially impacting stakeholders by enhancing the company’s capability to compete in the biosimilar market.

Xbrane Biopharma Announces SEK 200 Million Directed Share Issue
Jun 9, 2025

Xbrane Biopharma AB announced a directed issue of shares worth approximately SEK 200 million to institutional and qualified investors. This move is aimed at financing regulatory processes, paying suppliers, and supporting general corporate purposes. The company recently completed a transaction with Alvotech, selling its biosimilar candidate and parts of its organization, which is expected to reduce annual fixed costs significantly. The directed issue is seen as a strategic decision to strengthen the company’s financial position, diversify its shareholder base, and support the development and commercialization of its biosimilars.

Xbrane Biopharma Strengthens Focus with Sale of XB003 to Alvotech
Jun 4, 2025

Xbrane Biopharma has completed the sale of its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction strengthens Xbrane’s financial position, allowing the company to focus on its remaining programs, particularly Ximluci and Xdivane, and continue its work in biosimilar development to create value for shareholders and patients.

Xbrane Biopharma Advances Biosimilar Candidate Towards FDA Approval
May 23, 2025

Xbrane Biopharma AB has re-submitted its Biologics License Application to the US FDA for its biosimilar candidate to LUCENTIS® (ranibizumab), aimed at treating conditions such as age-related macular degeneration. The FDA has set a decision date for October 2025, contingent on successful re-inspections of manufacturing sites. This move underscores Xbrane’s commitment to providing cost-effective treatment alternatives and could enhance its position in the biosimilar market.

Xbrane Biopharma Strengthens Financial Position with Strategic Asset Sale
May 8, 2025

Xbrane Biopharma AB announced a strategic move to sell its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction is expected to strengthen Xbrane’s financial position by reducing annual fixed costs by around SEK 120 million and allowing the company to focus on its core products, Ximluci® and Xdivane™, which are anticipated to generate significant revenue through royalties and profit sharing. The company also reported strong growth for Ximluci® in Europe and is progressing with regulatory processes in the US, while preparing for a clinical trial for Xdivane™.

Xbrane Biopharma AB Announces Key Resolutions from Annual General Meeting
May 6, 2025

Xbrane Biopharma AB’s annual general meeting resulted in several key resolutions, including the adoption of the income statement and balance sheet, the decision not to distribute dividends, and the re-election of board members and auditors. The meeting also established remuneration for directors and committee members and set guidelines for senior executive remuneration, while withdrawing a proposal for issuing shares due to insufficient support.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.